Susquehanna International Group
VIRX

Susquehanna International Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Susquehanna International Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,800
Closed -$119K – 13951
2022
Q3 		$119K Buy
27,800
+1,000
+4% +$4.24K ﹤0.01% 11534
2022
Q2 		$104K Sell
26,800
-4,100
-13% -$11.7K ﹤0.01% 11445
2022
Q1 		$147K Buy
30,900
+17,000
+122% +$51.2K ﹤0.01% 11579
2021
Q4 		$51K Sell
13,900
-1,600
-10% -$8.54K ﹤0.01% 12532
2021
Q3 		$124K Sell
15,500
-4,700
-23% -$46.3K ﹤0.01% 11928
2021
Q2 		$229K Sell
20,200
-2,600
-11% -$26.1K ﹤0.01% 11309
2021
Q1 		$211K Buy
22,800
+18,314
+408% +$191K ﹤0.01% 11336
2020
Q4 		$31K Sell
4,486
-1,600
-26% -$8.35K ﹤0.01% 10842
2020
Q3 		$27K Buy
+6,086
New +$53.2K ﹤0.01% 10350
2020
Q2 		– Sell
-309
Closed -$4K – 11108
2020
Q1 		$4K Sell
309
-40
-11% -$868 ﹤0.01% 10120
2019
Q4 		$4K Sell
349
-460
-57% -$7.7K ﹤0.01% 9585
2019
Q3 		$20K Buy
+809
New +$23.3K ﹤0.01% 9952
2019
Q2 		– Sell
-906
Closed -$39K – 10957
2019
Q1 		$39K Buy
+906
New +$20.5K ﹤0.01% 8514
2018
Q4 		– Sell
-4,426
Closed -$310K – 10156
2018
Q3 		$310K Buy
4,426
+2,529
+133% +$192K ﹤0.01% 7424
2018
Q2 		$141K Buy
1,897
+1,511
+391% +$135K ﹤0.01% 8884
2018
Q1 		$37K Sell
386
-25
-6% -$4.29K ﹤0.01% 9038
2017
Q4 		$53K Buy
+411
New +$38.5K ﹤0.01% 8897
2017
Q3 		– Sell
-286
Closed -$27K – 9778
2017
Q2 		$27K Buy
+286
New +$32.8K ﹤0.01% 8988
2017
Q1 		– Sell
-857
Closed -$109K – 10174
2016
Q4 		$109K Sell
857
-1,009
-54% -$140K ﹤0.01% 9045
2016
Q3 		$285K Buy
1,866
+1,446
+344% +$204K ﹤0.01% 7018
2016
Q2 		$48K Sell
420
-11
-3% -$1.22K ﹤0.01% 8252
2016
Q1 		$49K Sell
431
-15
-3% -$2.27K ﹤0.01% 8671
2015
Q4 		$84K Sell
446
-201
-31% -$37.6K ﹤0.01% 8938
2015
Q3 		$110K Sell
647
-518
-44% -$187K ﹤0.01% 9089
2015
Q2 		$737K Sell
1,165
-2,457
-68% -$1.31M ﹤0.01% 6842
2015
Q1 		$1.86M Buy
3,622
+2,708
+296% +$1.37M ﹤0.01% 4449
2014
Q4 		$489K Sell
914
-1,547
-63% -$697K ﹤0.01% 7251
2014
Q3 		$3.69M Buy
2,461
+900
+58% +$1.3M ﹤0.01% 3513
2014
Q2 		$2.14M Buy
1,561
+535
+52% +$621K ﹤0.01% 4543
2014
Q1 		$1.42M Buy
1,026
+884
+623% +$1.03M ﹤0.01% 4889
2013
Q4 		$142K Buy
+142
New +$147K ﹤0.01% 8491
2013
Q3 		– Sell
-679
Closed -$742K – 8854
2013
Q2 		$742K Buy
+679
New +$757K ﹤0.01% 5462

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's VIRX Position: Q1 2024 in Review

Susquehanna International Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2024, closing a stake of 41,412 shares — an estimated $23.6K sold.

Susquehanna International Group first reported a position in VIRX in Q2 2013 and held it in 25 quarters. The position peaked at $1.72M in Q1 2015. 40 funds tracked by Wall St. Rank hold VIRX as of Q1 2024.

  • Susquehanna International Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 41,412 Viracta Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $23.6K.
  • Susquehanna International Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
  • Susquehanna International Group's Viracta Therapeutics, Inc. Common Stock position peaked at $1.72M in Q1 2015.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.